Active, not recruitingPhase 3NCT05704244
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ferring Pharmaceuticals
- Principal Investigator
- Global Clinical ComplianceFerring Pharmaceuticals
- Intervention
- FE 999326(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2022 – 2029
Study locations (24)
- Ferring Investigational Site, Nagakute-shi, Aichi-ken, Japan
- Ferring Investigational Site, Nagoya, Aichi-ken, Japan
- Ferring Investigational Site, Narita-shi, Chiba, Japan
- Ferring Investigational Site, Matsuyama, Ehime, Japan
- Ferring Investigational Site, Fukuoka, Fukuoka, Japan
- Ferring Investigational Site, Hiroshima, Hiroshima, Japan
- Ferring Investigational Site, Hakodate-shi, Hokkaido, Japan
- Ferring Investigational Site, Sapporo, Hokkaido, Japan
- Ferring Investigational Site, Hitachi-shi, Ibaraki, Japan
- Ferring Investigational Site, Tsukuba, Ibaraki, Japan
- Ferring Investigational Site, Kawasaki-shi, Kanagawa, Japan
- Ferring Investigational Site, Yokohama, Kanagawa, Japan
- Ferring Investigational Site, Nankoku-shi, Kochi, Japan
- Ferring Investigational Site, Tsu, Mie-ken, Japan
- Ferring Investigational Site, Sendai, Miyagi, Japan
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05704244 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University